What is the current valuation of the Vaccine Research Market as of 2024?

The Vaccine Research Market was valued at 58.71 USD Billion in 2024. Read More

What is the projected market valuation for the Vaccine Research Market in 2035?

The projected valuation for the Vaccine Research Market in 2035 is 270.84 USD Billion. Read More

What is the expected CAGR for the Vaccine Research Market during the forecast period 2025 - 2035?

The expected CAGR for the Vaccine Research Market during the forecast period 2025 - 2035 is 14.91%. Read More

What are the market segments for Vaccine Research based on vaccine type?

Market segments for Vaccine Research based on vaccine type include Live Attenuated, Inactivated, Recombinant, Conjugate, Subunit, Viral Vector, DNA, and mRNA Vaccines. Read More

What was the market size for Live Attenuated Vaccines in 2024?

The market size for Live Attenuated Vaccines was 8.0 USD Billion in 2024. Read More

How much is the market for Inactivated Vaccines projected to grow by 2035?

The market for Inactivated Vaccines is projected to grow to 45.0 USD Billion by 2035. Read More

What is the expected market size for Chronic Diseases vaccine segment by 2035?

The expected market size for the Chronic Diseases vaccine segment is projected to reach 80.0 USD Billion by 2035. Read More

Which target population segment has the highest market size in 2024?

In 2024, the Adults target population segment had the highest market size at 20.0 USD Billion. Read More

What delivery method segment is anticipated to have the largest market size by 2035?

The Intramuscular Injection delivery method segment is anticipated to have the largest market size, projected at 90.0 USD Billion by 2035. Read More

Vaccine Research Market

Q: Which companies are considered key players in the Vaccine Research Market?

Key players in the Vaccine Research Market include Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Sanofi, GSK, Novavax, Merck, and Bharat Biotech. Read More

ID: MRFR/HC/26248-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Vaccine Research Market Research Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Conjugate Vaccines, Subunit Vaccines, Viral Vector Vaccines, DNA Vaccines, mRNA Vaccines), By Disease Prevention (Infectious Diseases (e.g., Measles, Polio, Influenza), Chronic Diseases (e.g., Cancer, HIV/AIDS), Rare Diseases (e.g., Cystic Fibrosis, Hemophilia)), By Target Population (Pediatrics, Adults, Elderly, Pregnant Women), By Delivery Method (Intramuscular Injection, Subcutaneous Injection, Intranasal Delivery, Oral Administration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Vaccine Research Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)14.91%

2024 Market Size$ 58.71 Billion

2025 Market Size$ 67.46 Billion

2035 Market Size$ 270.84 Billion

Key Players

Pfizer

Moderna

Johnson & Johnson

AstraZeneca

Sanofi

GSK

Trends

Technological Integration
Collaborative Research Initiatives
Increased Public Engagement

Opportunities

Advancements in Biotechnology
Government Funding and Support
Emerging Markets and Demographic Shifts

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Live Attenuated Vaccines
  2. 4.1.2 Inactivated Vaccines
  3. 4.1.3 Recombinant Vaccines
  4. 4.1.4 Conjugate Vaccines
  5. 4.1.5 Subunit Vaccines
  6. 4.1.6 Viral Vector Vaccines
  7. 4.1.7 DNA Vaccines
  8. 4.1.8 mRNA Vaccines
2. 4.2 Healthcare, BY Disease Prevention (USD Billion)
  1. 4.2.1 Infectious Diseases
  2. 4.2.2 Chronic Diseases
  3. 4.2.3 Rare Diseases
3. 4.3 Healthcare, BY Target Population (USD Billion)
  1. 4.3.1 Pediatrics
  2. 4.3.2 Adults
  3. 4.3.3 Elderly
  4. 4.3.4 Pregnant Women
4. 4.4 Healthcare, BY Delivery Method (USD Billion)
  1. 4.4.1 Intramuscular Injection
  2. 4.4.2 Subcutaneous Injection
  3. 4.4.3 Intranasal Delivery
  4. 4.4.4 Oral Administration
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GSK (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novavax (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bharat Biotech (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY DISEASE PREVENTION
5. 6.5 US MARKET ANALYSIS BY TARGET POPULATION
6. 6.6 US MARKET ANALYSIS BY DELIVERY METHOD
7. 6.7 CANADA MARKET ANALYSIS BY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY DISEASE PREVENTION
9. 6.9 CANADA MARKET ANALYSIS BY TARGET POPULATION
10. 6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY DISEASE PREVENTION
14. 6.14 GERMANY MARKET ANALYSIS BY TARGET POPULATION
15. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD
16. 6.16 UK MARKET ANALYSIS BY TYPE
17. 6.17 UK MARKET ANALYSIS BY DISEASE PREVENTION
18. 6.18 UK MARKET ANALYSIS BY TARGET POPULATION
19. 6.19 UK MARKET ANALYSIS BY DELIVERY METHOD
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY DISEASE PREVENTION
22. 6.22 FRANCE MARKET ANALYSIS BY TARGET POPULATION
23. 6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE PREVENTION
26. 6.26 RUSSIA MARKET ANALYSIS BY TARGET POPULATION
27. 6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD
28. 6.28 ITALY MARKET ANALYSIS BY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY DISEASE PREVENTION
30. 6.30 ITALY MARKET ANALYSIS BY TARGET POPULATION
31. 6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY DISEASE PREVENTION
34. 6.34 SPAIN MARKET ANALYSIS BY TARGET POPULATION
35. 6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE PREVENTION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TARGET POPULATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY DISEASE PREVENTION
43. 6.43 CHINA MARKET ANALYSIS BY TARGET POPULATION
44. 6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD
45. 6.45 INDIA MARKET ANALYSIS BY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY DISEASE PREVENTION
47. 6.47 INDIA MARKET ANALYSIS BY TARGET POPULATION
48. 6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY DISEASE PREVENTION
51. 6.51 JAPAN MARKET ANALYSIS BY TARGET POPULATION
52. 6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE PREVENTION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TARGET POPULATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE PREVENTION
59. 6.59 MALAYSIA MARKET ANALYSIS BY TARGET POPULATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY DISEASE PREVENTION
63. 6.63 THAILAND MARKET ANALYSIS BY TARGET POPULATION
64. 6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE PREVENTION
67. 6.67 INDONESIA MARKET ANALYSIS BY TARGET POPULATION
68. 6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE PREVENTION
71. 6.71 REST OF APAC MARKET ANALYSIS BY TARGET POPULATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE PREVENTION
76. 6.76 BRAZIL MARKET ANALYSIS BY TARGET POPULATION
77. 6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY DISEASE PREVENTION
80. 6.80 MEXICO MARKET ANALYSIS BY TARGET POPULATION
81. 6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE PREVENTION
84. 6.84 ARGENTINA MARKET ANALYSIS BY TARGET POPULATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE PREVENTION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET POPULATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE PREVENTION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TARGET POPULATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE PREVENTION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TARGET POPULATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE PREVENTION
101. 6.101 REST OF MEA MARKET ANALYSIS BY TARGET POPULATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY DISEASE PREVENTION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY DISEASE PREVENTION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY TARGET POPULATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TARGET POPULATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.2.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.3.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.4.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.5.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.6.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.7.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.8.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.9.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.10.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.11.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.12.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.13.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.14.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.15.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.16.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.17.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.18.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.19.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.20.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.21.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.22.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.23.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.24.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.25.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.26.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.27.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.28.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.29.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
  3. 7.30.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Vaccine Research Market Segmentation

Vaccine Research Market By Type (USD Billion, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Conjugate Vaccines
Subunit Vaccines
Viral Vector Vaccines
DNA Vaccines
mRNA Vaccines

Vaccine Research Market By Disease Prevention (USD Billion, 2025-2035)

Infectious Diseases
Chronic Diseases
Rare Diseases

Vaccine Research Market By Target Population (USD Billion, 2025-2035)

Pediatrics
Adults
Elderly
Pregnant Women

Vaccine Research Market By Delivery Method (USD Billion, 2025-2035)

Intramuscular Injection
Subcutaneous Injection
Intranasal Delivery
Oral Administration

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”